5 recruiting, 3 completed, 2 active not recruiting, 2 terminated. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Active not recruiting 2, Completed 2, Terminated 1 |
| Phase 1 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
Follow Refractory High Grade B-Cell Lymphoma: new trials by email Literature Review of Refractory High Grade B-Cell Lymphoma trials Research Report on Refractory High Grade B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse golcadomide - Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 65 | 2024-06-14 | 2026-06-04 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Mayo Clinic | 10 | 2023-04-19 | 2026-04-22 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Completed | University of California, San Francisco | 23 | 2020-04-16 | 2023-08-21 | |
| Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy Electronic Health Record Review - Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Unknown | M.D. Anderson Cancer Center | 150 | 2020-04-02 | 2023-11-14 | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2018-10-24 | 2023-09-21 |
Lymphoma, Large B-Cell, Diffuse (10) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Composite Lymphoma (1) · Disease Progression (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Multiple Myeloma (1) · Neoplasms (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoma (12) · Lymphoproliferative Disorders (12) · Neoplasms by Histologic Type (12) · Lymphoma, B-Cell (11) · Neoplasms (11) · Lymphoma, Non-Hodgkin (10) · Disease Attributes (4) · Hematologic Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (2)
Biopsy (5) · Cyclophosphamide (5) · Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Leukapheresis (3) · axicabtagene ciloleucel (3) · fludarabine (3) · fludarabine phosphate (3) · Interleukin 1 Receptor Antagonist Protein (2) · Receptors, Interleukin-6 (2) · pembrolizumab (2) · ALX148 (1) · Blood Component Removal (1) · CT-P10 (1) · Disulfides (1)
M.D. Anderson Cancer Center (3) · AIDS Malignancy Consortium (1) · City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · Sumithira Vasu (1) · The Lymphoma Academic Research Organisation (1) · University of California, San Francisco (1) · University of Washington (1)
United States (12) · France (1)
Ariela Noy (1) · C. Babis Andreadis, MD (1) · Erel Joffe (1) · Francisco J Hernandez-ILizaliturri (1) · John M Timmerman, MD (1) · Mengyang Di, MD, PhD (1) · Paolo Strati (1) · Paolo Strati, MD (1) · Raphael E Steiner (1) · Stephen M. Ansell, MD, PhD (1) · Sumithira Vasu, MD (1) · Swetha Kambhampati (1)
PMID 39319495, PMID 37300573, PMID 41595202
P30CA033572 (1), R01CA276374 (1), UM1CA121947 (1), UM1CA186691 (1)